View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 25, 2020

Novavax launches Phase III trial of Covid-19 vaccine in UK

US-based biotechnology firm Novavax has started the first Phase III clinical trial of its potential Covid-19 vaccine, NVX-CoV2373, in the UK.

US-based biotechnology firm Novavax has started the first Phase III clinical trial of its potential Covid-19 vaccine, NVX-CoV2373, in the UK.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

Performed in collaboration with the UK Government’s Vaccines Taskforce, the trial will investigate the safety, efficacy and immunogenicity of NVX-CoV2373.

The study is designed to recruit up to 10,000 participants aged 18 to 84 years, with and without relevant comorbidities, over the coming four to six weeks.

It is intended to involve at least 25% of subjects aged above 65 years, and also prioritise groups most impacted by Covid-19, including racial and ethnic minorities.

During the randomised, placebo-controlled, observer-blinded trial, 50% of volunteers will be given two intramuscular injections of the vaccine candidate, 21 days apart, while the remaining will receive placebo.

The vaccine dose will consist of 5µg of protein antigen and 50µg Matrix‑M adjuvant.

Novavax added that under a co-administration sub-study, up to 400 participants will also be administered with a licensed seasonal influenza vaccine.

The first primary endpoint of the Phase III trial is first occurrence of PCR-confirmed symptomatic Covid-19 with onset at least seven days following the second vaccination in subjects with no prior SARS-CoV-2 infection.

Also, the trial will assess second primary endpoint as first occurrence of PCR-confirmed symptomatic moderate or severe Covid-19 with onset at least seven days after the second vaccination in those who had no previous infection from the virus.

An event-driven assessment depending on the number of volunteers with symptomatic or moderate/severe Covid-19 will be performed as the primary efficacy analysis.

Novavax Research and Development president Gregory Glenn said: “With a high level of SARS-CoV-2 transmission observed and expected to continue in the UK, we are optimistic that this pivotal Phase III clinical trial will enroll quickly and provide a near-term view of NVX-CoV2373’s efficacy.

“The data from this trial is expected to support regulatory submissions for licensure in the UK, EU and other countries.”

Based on Novavax recombinant protein nanoparticle technology, the Covid-19 vaccine candidate was also subjected to Phase I and Phase II trials.

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena